After detecting a strange combination of signals in the summer of 2025, astronomers believe they may have captured the first evidence of a unique phenomenon previously theorized, but never observed: a ...
An international team of astronomers has conducted optical and near-infrared observations of a supernova designated SN 2022ngb. As a result, it was found that SN 2022ngb is a faint and slow-evolving ...
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine ...
GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...
Commitment to sustainability – from financing green and blue bonds, to creating digital access for customers, to maintaining transparent governance for all stakeholders – can enable banks to create a ...
Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...
NEW ORLEANS, LA—A single subcutaneous injection of a novel, small-molecule glycoprotein IIb/IIIa inhibitor administered at first medical contact in patients with suspected STEMI improves the patency ...
Nello Mainolfi, Co-Founder, President, and CEO, stated that "our team has executed exceptionally well across all parts of our business," highlighting the company's focus on building a "global ...
In many a school auditorium, a theater kid could be spotted sitting cross-legged with a peanut butter and jelly sandwich, surrounded by peers who had just belted their way through the entire Hamilton ...
Management indicated the COVID-19 Phase IIb trial will continue follow-up for enrolled participants, with a comprehensive data readout anticipated in 2026 and data from the 400-person sentinel cohort ...
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to ...
LONDON, United Kingdom, July 19, 2025 (EZ Newswire) -- iib East Africa, opens new tab has earned international recognition for its leadership in sustainable banking, securing three prestigious awards ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback